

ABT-263 (Navitoclax)



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

5 mg

For Research Use Only. Not for Use in Diagnostic Procedures.

Background ABT-263 (Navitoclax) is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule

mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a K_i value of less than 1 nM (1). ABT-263 (Navitoclax) has been shown to have antitumor effects on small cell lung cancer (SCLC) xenograft models, resulting in complete tumor regression in some cases (2). Studies have shown that ABT-263 (Navitoclax) can enhance the effectiveness of chemotherapeutic and targeted agents against solid tumors (3). ABT-263 (Navitoclax) induces apoptosis, particularly in certain types of senescent cells

(4,5).

Molecular Formula C₄₇H₅₅CIF₃N₅O₆S₃

Molecular Weight 974.6 g/mol

Purity >98%

CAS 923564-51-6

Solubility Soluble in DMSO at 25 mg/ml.

Storage Store lyophilized at -20°C, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in

solution, store at -20°C and use within 3 months to prevent loss of potency. *Aliquot to avoid multiple*

freeze/thaw cycles.

Directions for UseABT-263 (Navitoclax) is supplied as a lyophilized powder. For a 5 mM stock, reconstitute 5 mg of powder

in 1.0 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired

effect.

Background References 1. Tse, C. et al. (2008) Cancer Res 68, 3421-8.

2. Shoemaker, A.R. et al. (2008) *Clin Cancer Res* 14, 3268-77.

3. Chen, J. et al. (2011) Mol Cancer Ther 10, 2340-9.

4. Zhu, Y. et al. (2016) Aging Cell 15, 428-35.

5. Zhu, Y. et al. (2015) *Aging Cell* 14, 644-58.

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any

applicable documentation, and (e) comply with any license, terms of service or similar agreement w respect to any third party products or services used by Customer in connection with the Products.